Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jun 01, 2011 (Vol. 31, No. 11)

DrugBank

URL:drugbank.ca
  • Many browse options, different classes of drugs
  • Nothing major

If you have any interest in pharmaceuticals, then you can “bank” on the fact that you’ll find DrugBank to be a fantastic resource. Of the “molecule-target interaction” variety, DrugBank is different from many of the other databases out there in its emphasis on pharmaceutical data. It contains FDA-approved biotech (protein/peptide) drugs, FDA-approved small molecule drugs, and a large number of experimental drugs. Together, these categories represent over 10,000 entries. As useful as it is to search databases, I always appreciate an option to browse. DrugBank, in fact, gives me (and you!) six such options: browse by drug name, therapeutic category, interacting gene/enzyme, pathway, chemical class, or association (target, enzyme, carrier, or transporter). For each compound, general chemical information is provided in addition to taxonomy, pharmacology, pharmacoeconomics, references, drug interactions, and targets.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »